Adnin Zaman

Dr. Adnin Zaman

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
CRCorey Rynders
Corey Rynders
ETElizabeth A Thomas
Elizabeth A Thomas
AZAdnin Zaman
Adnin Zaman
ZPZhaoxing Pan
Zhaoxing Pan
VCVictoria A. Catenacci
Victoria A. Catenacci
EMEdward L. Melanson
Edward L. Melanson
The current obesity epidemic is staggering in terms of its magnitude and public health impact. Current guidelines recommend continuous energy restriction (CER) along with a comprehensive lifestyle intervention as the cornerstone of obesity treatment, yet this approach produces modest weight loss on average. Recently, there has been increased interest in identifying alternative dietary weight loss strategies that involve restricting energy intake to certain periods of the day or prolonging the fasting interval between meals (i.e., intermittent energy restriction, IER). These strategies include intermittent fasting (IMF; >60% energy restriction on 2–3 days per week, or on alternate days) and time-restricted feeding (TRF; limiting the daily period of food intake to 8–10 h or less on most days of the week). Here, we summarize the current evidence for IER regimens as treatments for overweight and obesity. Specifically, we review randomized trials of ≥8 weeks in duration performed in adults with overweight or obesity (BMI ≥ 25 kg/m2) in which an IER paradigm (IMF or TRF) was compared to CER, with the primary outcome being weight loss. Overall, the available evidence suggests that IER paradigms produce equivalent weight loss when compared to CER, with 9 out of 11 studies reviewed showing no differences between groups in weight or body fat loss.

18 August 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CBCarolyn T. Bramante
Carolyn T. Bramante
JHJared D. Huling
Jared D. Huling
CTChristopher J. Tignanelli
Christopher J. Tignanelli
JBJohn B. Buse
John B. Buse
DLDavid M. Liebovitz
David M. Liebovitz
TMThomas A. Murray
Thomas A. Murray
Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. In this phase 3, double-blind, randomized, placebo-controlled trial, we used a 2-by-3 factorial design to test the effectiveness of three repurposed drugs — metformin, ivermectin, and fluvoxamine — in preventing serious SARS-CoV-2 infection in nonhospitalized adults who had been enrolled within 3 days after a confirmed diagnosis of infection and less than 7 days after the onset of symptoms. The patients were between the ages of 30 and 85 years, and all had either overweight or obesity. The primary composite end point was hypoxemia (≤93% oxygen saturation on home oximetry), emergency department visit, hospitalization, or death. All analyses used controls who had undergone concurrent randomization and were adjusted for SARS-CoV-2 vaccination and receipt of other trial medications. A total of 1431 patients underwent randomization; of these patients, 1323 were included in the primary analysis. The median age of the patients was 46 years; 56% were female (6% of whom were pregnant), and 52% had been vaccinated. The adjusted odds ratio for a primary event was 0.84 (95% confidence interval [CI], 0.66 to 1.09; P=0.19) with metformin, 1.05 (95% CI, 0.76 to 1.45; P=0.78) with ivermectin, and 0.94 (95% CI, 0.66 to 1.36; P=0.75) with fluvoxamine. In prespecified secondary analyses, the adjusted odds ratio for emergency department visit, hospitalization, or death was 0.58 (95% CI, 0.35 to 0.94) with metformin, 1.39 (95% CI, 0.72 to 2.69) with ivermectin, and 1.17 (95% CI, 0.57 to 2.40) with fluvoxamine. The adjusted odds ratio for hospitalization or death was 0.47 (95% CI, 0.20 to 1.11) with metformin, 0.73 (95% CI, 0.19 to 2.77) with ivermectin, and 1.11 (95% CI, 0.33 to 3.76) with fluvoxamine. None of the three medications that were evaluated prevented the occurrence of hypoxemia, an emergency department visit, hospitalization, or death associated with Covid-19. (Funded by the Parsemus Foundation and others; COVID-OUT ClinicalTrials.gov number, NCT04510194.)

26 April 2022 in Obesity
Verified
Journal Article
Closed access
ETElizabeth A Thomas
Elizabeth A Thomas
AZAdnin Zaman
Adnin Zaman
KSKelsey J. Sloggett
Kelsey J. Sloggett
SSSheila Steinke
Sheila Steinke
LGLaura Grau
Laura Grau
CRCorey Rynders
Corey Rynders

29 December 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
ETElizabeth A Thomas
Elizabeth A Thomas
AZAdnin Zaman
Adnin Zaman
MCMarc-Andre Cornier
Marc-Andre Cornier
VCVictoria A. Catenacci
Victoria A. Catenacci
ETEmma J. Tussey
Emma J. Tussey
CRCorey Rynders
Corey Rynders
Accumulating evidence suggests that later timing of energy intake (EI) is associated with increased risk of obesity. In this study, 83 individuals with overweight and obesity underwent assessment of a 7-day period of data collection, including measures of body weight and body composition (DXA) and 24-h measures of EI (photographic food records), sleep (actigraphy), and physical activity (PA, activity monitors) for 7 days. Relationships between body mass index (BMI) and percent body fat (DXA) with meal timing, sleep, and PA were examined. For every 1 h later start of eating, there was a 1.25 (95% CI: 0.60, 1.91) unit increase in percent body fat (False Discovery Rate (FDR) adjusted p value = 0.010). For every 1 h later midpoint of the eating window, there was a 1.35 (95% CI: 0.51, 2.19) unit increase in percent body fat (FDR p value = 0.029). For every 1 h increase in the end of the sleep period, there was a 1.64 (95% CI: 0.56, 2.72) unit increase in percent body fat (FDR p value = 0.044). Later meal and sleep timing were also associated with lower PA levels. In summary, later timing of EI and sleep are associated with higher body fat and lower levels of PA in people with overweight and obesity.

4 August 2021 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
SISean Iwamoto
Sean Iwamoto
LALayla A. Abushamat
Layla A. Abushamat
AZAdnin Zaman
Adnin Zaman
AMAnthony J. Millard
Anthony J. Millard
MCMarc-Andre Cornier
Marc-Andre Cornier

11 January 2021 in Endocrinology and Metabolism Clinics of North America
Verified
Journal Article
Closed access
AZAdnin Zaman
Adnin Zaman
MRMicol S. Rothman
Micol S. Rothman